secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2023-10-31T23:59:59+00:00
Accession:  0001453687-23-000070
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Selecta transitions SEL-212 manufacturing to Sobi; CMO goes part-time
---------------------------------------------------------------------

- Selecta granted Sobi exclusive license to manufacture ImmTOR for SEL-212; Sobi assumes all manufacturing and commercial supply.
- 15 Selecta employees expected to become Sobi employees; CMO Peter Traber moves to part-time at Selecta and consultant to Sobi.
- Selecta retains eligibility for up to $615M in remaining milestones and tiered double-digit royalties on SEL-212 net sales.
- BLA submission for SEL-212 on track for first half of 2024; peak U.S. sales potential estimated at >$700M.
- Dr. Traber's base salary reduced to $250,000; severance benefits tied to pre-amendment salary in certain termination scenarios.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000145368723000070/0001453687-23-000070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000145368723000070/selb-20231031.htm
  HTML page:      https://secwatch.observer/filing/0001453687-23-000070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer